Live Evaluations
Baby Got JAK: Case Conversations on The Role of JAK Inhibitors in Dermatology
About
Baby Got JAK: Case Conversations on The Role of JAK Inhibitors in Dermatology
This activity is supported by an educational grant from Incyte.
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe the pathophysiology of itch in dermatologic conditions and how JAK inhibitors target the itch pathway
Outline the role of JAK inhibitors for the management of dermatologic conditions
Review key itch data for JAK inhibitors in skin diseases
Identify patients who would benefit from JAK inhibitors to manage dermatologic conditions
Intended Audience
Faculty
Mona Shahriari, MD
Dermatologist, Yale University School of Medicine
Central CT Dermatology
Cromwell, CT
Lisa Swanson, MD
Pediatric Dermatologist
Ada West Dermatology
Boise, ID
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union
Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB
Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant
Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis
Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.